Early phase trials of novel hearing therapeutics: Avenues and opportunities

Anne G.M. Schilder; Matthew P. Su; Rishi Mandavia; Caroline R. Anderson; Evie Landry; Tanjinah Ferdous; Helen Blackshaw

doi:10.1016/j.heares.2019.07.003

Early phase trials of novel hearing therapeutics: Avenues and opportunities

Anne G.M. Schilder
, Matthew P. Su
, Rishi Mandavia
, Caroline R. Anderson
, Evie Landry
, Tanjinah Ferdous
, Helen Blackshaw

University College London
National Institute for Health and Care Research
NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) North Thames
University of British Columbia

Research output: Contribution to journal › Review article › peer-review

21 Scopus citations

Abstract

Novel hearing therapeutics are rapidly progressing along the innovation pathway and into the clinical trial domain. Because these trials are new to the hearing community, they come with challenges in terms of trial design, regulation and delivery. In this paper, we address the key scientific and operational issues and outline the opportunities for interdisciplinary and international collaboration these trials offer. Vital to the future successful implementation of these therapeutics is to evaluate their potential for adoption into healthcare systems, including consideration of their health economic value. This requires early engagement with all stakeholder groups along the hearing innovation pathway.

Original language	English
Pages (from-to)	175-186
Number of pages	12
Journal	Hearing Research
Volume	380
DOIs	https://doi.org/10.1016/j.heares.2019.07.003
State	Published - 1 Sep 2019
Externally published	Yes

Keywords

Aetiology
Clinical trial
Diagnosis
Genetics
Hearing
Therapeutics

Access to Document

10.1016/j.heares.2019.07.003

Cite this

@article{18c2959dc0d242bd8c50940f31928174,

title = "Early phase trials of novel hearing therapeutics: Avenues and opportunities",

abstract = "Novel hearing therapeutics are rapidly progressing along the innovation pathway and into the clinical trial domain. Because these trials are new to the hearing community, they come with challenges in terms of trial design, regulation and delivery. In this paper, we address the key scientific and operational issues and outline the opportunities for interdisciplinary and international collaboration these trials offer. Vital to the future successful implementation of these therapeutics is to evaluate their potential for adoption into healthcare systems, including consideration of their health economic value. This requires early engagement with all stakeholder groups along the hearing innovation pathway.",

keywords = "Aetiology, Clinical trial, Diagnosis, Genetics, Hearing, Therapeutics",

author = "Schilder, \{Anne G.M.\} and Su, \{Matthew P.\} and Rishi Mandavia and Anderson, \{Caroline R.\} and Evie Landry and Tanjinah Ferdous and Helen Blackshaw",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = sep,

day = "1",

doi = "10.1016/j.heares.2019.07.003",

language = "English",

volume = "380",

pages = "175--186",

journal = "Hearing Research",

issn = "0378-5955",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - Early phase trials of novel hearing therapeutics

T2 - Avenues and opportunities

AU - Schilder, Anne G.M.

AU - Su, Matthew P.

AU - Mandavia, Rishi

AU - Anderson, Caroline R.

AU - Landry, Evie

AU - Ferdous, Tanjinah

AU - Blackshaw, Helen

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Novel hearing therapeutics are rapidly progressing along the innovation pathway and into the clinical trial domain. Because these trials are new to the hearing community, they come with challenges in terms of trial design, regulation and delivery. In this paper, we address the key scientific and operational issues and outline the opportunities for interdisciplinary and international collaboration these trials offer. Vital to the future successful implementation of these therapeutics is to evaluate their potential for adoption into healthcare systems, including consideration of their health economic value. This requires early engagement with all stakeholder groups along the hearing innovation pathway.

AB - Novel hearing therapeutics are rapidly progressing along the innovation pathway and into the clinical trial domain. Because these trials are new to the hearing community, they come with challenges in terms of trial design, regulation and delivery. In this paper, we address the key scientific and operational issues and outline the opportunities for interdisciplinary and international collaboration these trials offer. Vital to the future successful implementation of these therapeutics is to evaluate their potential for adoption into healthcare systems, including consideration of their health economic value. This requires early engagement with all stakeholder groups along the hearing innovation pathway.

KW - Aetiology

KW - Clinical trial

KW - Diagnosis

KW - Genetics

KW - Hearing

KW - Therapeutics

UR - https://www.scopus.com/pages/publications/85068888241

U2 - 10.1016/j.heares.2019.07.003

DO - 10.1016/j.heares.2019.07.003

M3 - Review article

C2 - 31319285

AN - SCOPUS:85068888241

SN - 0378-5955

VL - 380

SP - 175

EP - 186

JO - Hearing Research

JF - Hearing Research

ER -

Early phase trials of novel hearing therapeutics: Avenues and opportunities

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this